Q32 reports maintained hair-growth responses after treatment withdrawal
Q32 Bio ($QTTB) reported new off-treatment follow-up from the open-label Part B of its SIGNAL-AA study of bempikibart for severe alopecia areata. Among 12 patients who had shown hair growth by the end of 36 weeks of treatment and entered follow-up, all maintained response through 16 weeks without dosing under the study’s definition. Responses deepened in 42% of that subgroup. The findings could inform less frequent maintenance dosing as Q32 prepares a registration-directed program for the first
0